3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
125
Squamous Cell Carcinoma of Head and Neck
64
Melanoma
64
Parkinson Disease 4, Autosomal Dominant Lewy Body
52
Lung Neoplasms
50
Triple Negative Breast Neoplasms
46
Neoplasm Metastasis
45
Breast Neoplasms
41
Neoplasms
38
Colorectal Neoplasms
34
Head and Neck Neoplasms
29
Carcinoma, Renal Cell
29
Endometrial Neoplasms
28
Ovarian Neoplasms
27
Carcinoma, Transitional Cell
22
Urinary Bladder Neoplasms
21
Stomach Neoplasms
17
Carcinoma
16
Pancreatic Neoplasms
15
Uterine Cervical Neoplasms
14
Esophageal Neoplasms
13
Recurrence
12
Sarcoma
11
Hodgkin Disease
11
Carcinoma, Squamous Cell
11
Carcinoma, Hepatocellular
11
Brain Neoplasms
11
Cholangiocarcinoma
10
Skin Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Interventions
Bevacizumab
3
contrast agent BR1
2
pralsetinib
1
pembrolizumab
1
Pemetrexed
1
Paclitaxel
1
Microbubbles
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Biopsy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Nerve Tissue
×
pembrolizumab
×
90 days
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts